Marubeni Corporation (“Marubeni”) has concluded an agreement with PT Lippo Karawaci TbK (“Lippo Karawaci”), the core company of the Lippo Group (“Lippo”) for a joint study on the development of a centralized clinical laboratory testing service(*) in Indonesia.
Indonesia has the 4th largest population in the world, and a large nominal GDP of about US$932.5B(**), and is regarded as one of the countries in Asia with the greatest growth potential. However, growing demand for healthcare has accelerated due to healthcare policies by Department of Health which is requiring the country to develop medical facilities and improve the quality of medical services. To address these demands, Marubeni and Lippo will examine the possibility of introducing high-quality Japanese clinical laboratory testing services which can contribute to the improvement in the quality of medical services in Indonesia.
Lippo Karawaci provides medical services through its subsidiary company, PT Siloam International Hospitals TbK (“Siloam”), the largest private hospital group in Indonesia with general hospitals nationwide.
Marubeni aims to establish a new business base in the healthcare and medical field in Indonesia, and develop similar kinds of business including hospital-related business and medical services, not only in Indonesia but in other Asian countries as well.
(*) Clinical laboratory testing service: A testing service which examines the blood, urine or feces collected from patients, including hematology, biochemical and immunological tests
(**) Ref: IMF World Economic Outlook Databases October 2017